Pharmaceuticals Global Published · instant download

Global Peptide Therapy Market Strategic Research Report

Global Peptide Therapy Market Strategic Research Report
$3,500 USD
Global Peptide Therapy Market Strategic Research Report

By Type: GLP-1/GIP Receptor Agonist Therapy, Somatostatin Analog Therapy, LHRH Analog / GnRH Therapy, Hormonal Peptide Therapy, Immunomodulatory Peptide Therapy, Bone & Growth Peptide Therapy, Oncology Peptide Therapy and Other Peptide Therapies

By Application: Diabetes & Obesity, Oncology (Cancer Treatment), Endocrinology, Reproductive Health & Urology, Immunology & Transplant, Bone Metabolism & Mineral Disorders, Rare Diseases & Orphan Conditions and Other Applications

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Novo Nordisk A/S, Eli Lilly and Company, Novartis AG, Ipsen SA, AbbVie Inc., Teva Pharmaceutical Industries, AstraZeneca plc, Ferring Pharmaceuticals, Pfizer Inc., Amgen Inc.

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2031
Length: 161 pages
Market size 2025
$84.2B
Billion USD
Forecast CAGR
14.74%
2025-2031
Forecast 2031
$192.1B
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

The global peptide therapy market is undergoing an unprecedented structural transformation driven by the GLP-1 revolution - the extraordinary commercial success of GLP-1 receptor agonist drugs for diabetes and obesity, representing one of the most significant pharmaceutical market growth stories of the decade.

This report covers the full spectrum of peptide therapy industry across all major global markets for the forecast period 2026–2031, with 2025 as the base year.

As per this report, the global peptide therapy market, which was worth USD 84.2 billion in 2025, is expected to grow at a CAGR of 14.74% between 2026 and 2031 thus making peptide therapeutics the fastest-growing major drug class in pharmaceutical history, on track to surpass oncology as the world's largest therapeutic market category by 2028–2030. The global peptide therapy market is expected to be worth USD 196.5 billion by 2031. Global peptide therapy market is expected to be worth USD 196.50 billion by 2031.

The global peptide therapy market volume, which was 20.2 billion dosage units in 2025, is expected to grow at a CAGR of 21.24% between 2026 and 20231. The global peptide therapy market volume is expected to reach 65.5 billion dosage units by 2031. The global peptide therapy volume is expected to grow substantially faster than value, indicating expansion into price-sensitive populations and geographies.

GLP-1/GIP Receptor Agonist Therapy is the largest segment type in the global peptide therapy market at estimated 81.5% market share by value in 2026 and is expected to grow at a CAGR of 15.92% by value and 23.40% by volume during 2026-2031. This segment is led by Novo Nordisk's semaglutide (Ozempic/Wegovy) and Eli Lilly's tirzepatide (Mounjaro/Zepbound) which are expected to command 57.4% of the market in 2026. This duopoly reflects the blockbuster nature of GLP-1 therapies, though pricing pressure from biosimilar and generic competition is evident in the declining average selling price.

Oncology Peptide Therapy which are estimated to have 4.1% market share by value in 2026 and is expected to grow second fastest at a CAGR of 11.79% by value and 17.98% by volume during 2026-2031.

Diabetes & Obesity is the largest application segment in the global peptide therapy market. The growth of this segment is driven by the approval of GLP-1 therapies for obesity treatment (particularly Novo Nordisk's Wegovy and Lilly's Zepbound) has unlocked an enormous new patient population, transforming semaglutide and tirzepatide from diabetes-focused drugs into blockbuster obesity treatments.

Oncology (Cancer Treatment) application segment is expected to grow at a CAGR of 8.84% by value and 15.25% by volume during 2026-2031.

North America leads with estimated 49.8% market share in 2026, driven by United States which dominates the North American market, benefiting from the highest drug pricing globally and fastest GLP-1 adoption rates. United States GLP-1 prescriptions reached $32 billion in 2024, positioning the country as the critical revenue driver for pharmaceutical manufacturers.

Asia-Pacific is the fastest growing region at a CAGR of 17.07% by value and 21.43% by volume during 2026-2031, driven by China’s 140 million diabetics and NMPA approval of Ozempic in 2021, Japan's strong adoption following PMDA approval of Ozempic (2021) and Wegovy (2023) and South Korea's accelerate GLP-1 access.

India emerges as the fastest-growing Asia Pacific sub-market (19.89% CAGR) leveraging GLP-1 biosimilar production and growing middle-class population.

Europe is the expected to have second largest market share by value at 24.4% in 2026 and grow at a CAGR of 12.59% by value and 19.52% by volume during the forecast period of 2026-2031.  But Europe’s peptide therapy market is expected to decline in relative share as the United States market grows faster. Key Europe peptide therapy markets include Germany (16.5% of European market), France (13.1%), and the United Kingdom (13.4%), where NHS reimbursement decisions significantly impact adoption.

Middle East & Africa peptide therapy market is expected to show second highest growth potential (16.26% CAGR) fueled by Saudi Arabia highest global T2D prevalence (24%, International Diabetes Federation (IDF) 2024) and UAE premium market.

The global peptide therapy market is experiencing a structural inflection point driven by GLP-1/GIP agonists for diabetes and obesity. Market value will nearly double to USD 196.5 billion by 2031, representing historic pharma market expansion. However, this growth masks significant price deflation and competitive consolidation among incumbent players. Success will require sustained innovation in next-generation peptides, geographic diversification beyond North America, and proactive management of pricing pressure in mature markets. The next five years will reshape the competitive landscape in favor of companies with strong GLP-1 pipelines and emerging market capabilities.

Scope of Global Peptide Therapy Market Strategic Research Report 2026-2031

  • This report provides forecast data by value (in USD billion) and volume (in billion dosage units) till 2031 for the global peptide therapy market.
  • This report provides segment by type (GLP-1/GIP Receptor Agonist Therapy, Somatostatin Analog Therapy, LHRH Analog / GnRH Therapy, Hormonal Peptide Therapy, Immunomodulatory Peptide Therapy, Bone & Growth Peptide Therapy, Oncology Peptide Therapy and Other Peptide Therapies) forecast data by value (in USD billion) and volume (in billion dosage units) for the global peptide therapy market till 2031.
  • This report provides application segments (Diabetes & Obesity, Oncology (Cancer Treatment), Endocrinology, Reproductive Health & Urology, Immunology & Transplant, Bone Metabolism & Mineral Disorders, Rare Diseases & Orphan Conditions and Other Applications) forecast data by value (in USD billion) and volume (in billion dosage units) for the global peptide therapy market till 2031.
  • This report provides region-wise (Asia-Pacific, North America, Europe, Middle East & Africa, Latin America) forecast data by value (in USD billion) and volume (in billion dosage units) for the global peptide therapy market till 2031.
  • This report also provides country-wise forecast data by value (in USD billion) and volume (in billion dosage units) for China, Japan, India, South Korea, Australia, Rest of Asia Pacific, United States, Canada, Mexico, Germany, France, United Kingdom, Italy, Spain, Rest of Europe, Saudi Arabia, UAE, Israel, South Africa, Turkey, Rest of Middle East & Africa, Brazil, Mexico, Argentina, Colombia and  Rest of Latin America.
  • This report identifies key growth drivers and inhibitors (pain points) affecting the global peptide therapy market.
  • This report provides SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis , company profile including revenue (in USD billion), sale volume (billion dosage units), average selling price (ASP) and gross margin (%) for 2020-2025 along with competitive landscape for 10 key companies (Novo Nordisk A/S, Eli Lilly and Company, Novartis AG, Ipsen SA, AbbVie Inc., Teva Pharmaceutical Industries, AstraZeneca plc, Ferring Pharmaceuticals, Pfizer Inc. and Amgen Inc.) in the global peptide therapy market.
  • This report provides Porter’s Five Forces analysis for global peptide therapy market.
  • This report provides PESTLE (political, economic, social, technological, legal and environmental) analysis for global peptide therapy market.
  • This report provides SWOT (Strengths, Weaknesses, Opportunities and Threats) analysis for global peptide therapy market.
  • This report identifies key future trends in the global peptide therapy market.

Segment by Type in Global Peptide Therapy Market

  • GLP-1/GIP Receptor Agonist Therapy
  • Somatostatin Analog Therapy
  • LHRH Analog / GnRH Therapy
  • Hormonal Peptide Therapy
  • Immunomodulatory Peptide Therapy
  • Bone & Growth Peptide Therapy
  • Oncology Peptide Therapy
  • Other Peptide Therapies

Segment by Application in Global Peptide Therapy Market

  • Diabetes & Obesity
  • Oncology (Cancer Treatment)
  • Endocrinology
  • Reproductive Health & Urology
  • Immunology & Transplant
  • Bone Metabolism & Mineral Disorders
  • Rare Diseases & Orphan Conditions
  • Other Applications

Segment by Region in Global Peptide Therapy Market

  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Israel
    • South Africa
    • Turkey
    • Rest of Middle East & Africa
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of Latin America

Who can use the Global Peptide Therapy Market Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the peptide therapy market. Some of intended user for this report are:

  • C-level executives
  • Company Directors
  • Industry consultants
  • Marketing professionals
  • Business development professionals
  • Management consultants
  • Investment managers
  • Financial professionals
  • Venture Capitalists
  • Bank Managers
  • M&A Managers
  • Auditors
  • Anyone operating in peptide therapy industry value chain.

Market snapshot

Global Peptide Therapy Market Strategic Research Report snapshot, 2025–2031

Source: Market Research Reports
Market size CAGR 14.74%
Regional growth momentum
Market share by segment
Key metrics
Base value
$84.2B
2025
Forecast
$192.1B
2031
CAGR
14.74%
2025–2031
Regiones
5
global
Key companies
Novo Nordisk A/SEli Lilly and CompanyNovartis AGIpsen SAAbbVie Inc.Teva Pharmaceutical IndustriesAstraZeneca plcFerring Pharmaceuticals
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
GLP-1/GIP Receptor Agonist TherapySomatostatin Analog TherapyLHRH Analog / GnRH TherapyHormonal Peptide TherapyImmunomodulatory Peptide TherapyBone & Growth Peptide TherapyOncology Peptide Therapy and Other Peptide Therapies
By Application
Diabetes & ObesityOncology (Cancer Treatment)EndocrinologyReproductive Health & UrologyImmunology & TransplantBone Metabolism & Mineral DisordersRare Diseases & Orphan Conditions and Other Applications

Table of contents

Click a chapter to expand
01Executive Summary
  • Scope of Global Peptide Therapy Market Strategic Research Report 2026-2031
  • Research Methodology
02Forecast for Global Peptide Therapy Market 2026-2031
  • 2.1 Overall Global Peptide Therapy Market Forecast 2026-2031 by Value (in USD billion)
  • 2.2 Overall Global Peptide Therapy Market Forecast 2026-2031 by Volume (in Billion Dosage Units)
03Segment by Type Market Share in Global Peptide Therapy Market 2026-2031
  • 3.1 Global GLP-1/GIP Receptor Agonist Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 3.2 Global Somatostatin Analog Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 3.3 Global LHRH Analog / GnRH Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 3.4 Global Hormonal Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 3.5 Global Immunomodulatory Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 3.6 Global Bone & Growth Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 3.7 Global Oncology Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 3.8 Global Other Peptide Therapies Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
04Segment by Application Market Share in Global Peptide Therapy Market 2026-2031
  • 4.1 Global Diabetes & Obesity Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 4.2 Global Oncology (Cancer Treatment) Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 4.3 Global Endocrinology Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 4.4 Global Reproductive Health & Urology Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 4.5 Global Immunology & Transplant Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 4.6 Global Bone Metabolism & Mineral Disorders Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 4.7 Global Rare Diseases & Orphan Conditions Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 4.8 Global Other Applications Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
05Region-Wise Market Share in Global Peptide Therapy Market 2026-2031
  • 5.1 Asia-Pacific Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.1.1 China Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.1.2 Japan Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.1.3 India Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.1.4 South Korea Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.1.5 Australia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.1.8 Rest of Asia Pacific Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.2 North America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.2.1 USA Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.2.2 Canada Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.3 Europe Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.3.1 Germany Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.3.2 France Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.3.3 United Kingdom Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.3.4 Italy Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.3.5 Spain Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.3.6 Rest of Europe Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.4 Middle East & Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.4.1 Saudi Arabia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.4.2 UAE Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.4.3 Israel Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.4.4 South Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.4.5 Turkey Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.4.6 Rest of Middle East & Africa Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.5 Latin America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.5.1 Brazil Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.5.2 Mexico Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.5.3 Argentina Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.5.4 Colombia Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.5.5 Rest of Latin America Peptide Therapy Market Value (USD billion) and Volume (Billion Dosage Units) Forecast 2026-2031
  • 5.6 Top 15 Countries in Peptide Therapy Market by 2031 Value (in USD billion)
06Key Growth Drivers for Global Peptide Therapy Market
  • 6.1 GLP-1 Global Obesity Epidemic & Disease Burden
  • 6.2 Regulatory Milestone Cascade Creating New Market Segments
  • 6.3 PRRT and Radioligand Peptide Oncology Expansion
  • 6.4 Next-Generation Peptide Drug Innovation Pipeline
  • 6.5 GLP-1 Biosimilar Volume Expansion in Emerging Markets
  • 6.6 AI-Driven Peptide Drug Discovery Accelerating Pipeline
07Key Pain Areas / Growth Inhibitors for Global Peptide Therapy Market
  • 7.1 Affordability & Insurance Coverage Gaps
  • 7.2 API Supply Constraints and Manufacturing Complexity
  • 7.3 Long-Term Safety, Durability & Weight Regain Concerns
  • 7.4 Patent Litigation and Biosimilar Market Entry Complexity
  • 7.5 Geopolitical Risk: BIOSECURE Act and Chinese API Dependency
  • 7.6 Market Concentration Risk - Two-Company Duopoly
08Key Players in Global Peptide Therapy – Competitive Landscape and SWOT Analysis
  • 8.1 Novo Nordisk A/S
  • 8.1.1 Novo Nordisk A/S Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.1.2 SWOT Analysis of Novo Nordisk A/S
  • 8.2 Eli Lilly and Company
  • 8.2.1 Eli Lilly and Company Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.2.2 SWOT Analysis of Eli Lilly and Company
  • 8.3 Novartis AG
  • 8.3.1 Novartis AG Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.3.2 SWOT Analysis of Novartis AG
  • 8.4 Ipsen SA
  • 8.4.1 Ipsen SA Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.4.2 SWOT Analysis of Ipsen SA
  • 8.5 AbbVie Inc.
  • 8.5.1 AbbVie Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.5.2 SWOT Analysis of AbbVie Inc.
  • 8.6 Teva Pharmaceutical Industries
  • 8.6.1 Teva Pharmaceutical Industries Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.6.2 SWOT Analysis of Teva Pharmaceutical Industries
  • 8.7 AstraZeneca plc
  • 8.7.1 AstraZeneca plc Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.7.2 SWOT Analysis of AstraZeneca plc
  • 8.8 Ferring Pharmaceuticals
  • 8.8. Ferring Pharmaceuticals Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.8.2 SWOT Analysis of Ferring Pharmaceuticals
  • 8.9 Pfizer Inc.
  • 8.9.1 Pfizer Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.9.2 SWOT Analysis of Pfizer Inc.
  • 8.10 Amgen Inc.
  • 8.10.1 Amgen Inc. Revenue, Volume, Average Selling Price (ASP) and Gross Margin (2020-2025E)
  • 8.10.2 SWOT Analysis of Amgen Inc.
09Competitive Landscape of Key Players in the Global Peptide Therapy Market
  • 9.1 Revenue Comparison 2020–2025E (Peptide Therapy Drug Sales, USD Million)
  • 9.2 Revenue Growth Analysis: Winners & Laggards
  • 9.3 Product Coverage Matrix
  • 9.4 Geographic Coverage Matrix
  • 9.5 Strategic Capability Benchmarking
  • 9.6 Head-to-Head: Novo Nordisk vs. Eli Lilly - The GLP-1 Duopoly Battle
  • 9.7 Strategic Positioning Framework
  • 9.8 M&A Activity, Partnerships & Strategic Moves (2023–2026)
  • 9.9 Competitive Summary Scorecard
10Porter’s Five Forces Analysis of Global Peptide Therapy Market
  • 10.1 Bargaining Power of Suppliers: Low-Medium
  • 10.2 Bargaining Power of Buyers: Medium–High
  • 10.3 Threat of New Entrants: Low
  • 10.4 Threat of Substitution: Low–Medium
  • 10.5 Intensity of Competitive Rivalry: Medium-High
11PESTLE Analysis of Global Peptide Therapy Market
  • 11.1 Political (P)
  • 11.2 Economic (E)
  • 11.3 Social (S)
  • 11.4 Technological (T)
  • 11.5 Legal (L)
  • 11.6 Environmental (E)
12SWOT Analysis of Global Peptide Therapy Market
13Future Trends in Global Peptide Therapy Market
  • List of Exhibits
  • Notes
  • Company Information

Tables and figures

List of Exhibits

  • Exhibit 1.1 Global Peptide Therapy Market 2026-2031 Infographic
  • Exhibit 2.1 Forecast of Global Peptide Therapy Market Value 2022-2031 (in USD billion)
  • Exhibit 2.2 Forecast of Global Peptide Therapy Market Volume 2022-2031 (in Billion Dosage Units)
  • Exhibit 3.1 Segment by Type Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
  • Exhibit 3.2 Segment by Type Market Share in Global Peptide Therapy Market 2026 (in % and Billion Dosage Units)
  • Exhibit 3.3 Segment by Type Wise Value CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
  • Exhibit 3.4 Segment by Type Wise Volume CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
  • Exhibit 3.5 Forecast of Global GLP-1/GIP Receptor Agonist Therapy Market Value 2022-2031 (in USD billion)
  • Exhibit 3.6 Forecast of Global GLP-1/GIP Receptor Agonist Therapy Market Volume 2022-2031 (in Billion Dosage Units)
  • Exhibit 3.7 Forecast of Global Somatostatin Analog Therapy Market Value 2022-2031 (in USD billion)
  • Exhibit 3.8 Forecast of Global Somatostatin Analog Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 3.9 Forecast of Global LHRH Analog / GnRH Therapy Market Value 2022-2031 (in USD billion)
  • Exhibit 3.10 Forecast of Global LHRH Analog / GnRH Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 3.11 Forecast of Global Hormonal Peptide Therapy Market Value 2022-2031 (in USD billion)
  • Exhibit 3.12 Forecast of Global Hormonal Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 3.13 Forecast of Global Immunomodulatory Peptide Therapy Market Value 2022-2031 (in USD billion)
  • Exhibit 3.14 Forecast of Global Immunomodulatory Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 3.15 Forecast of Global Bone & Growth Peptide Therapy Market Value 2022-2031 (in USD billion)
  • Exhibit 3.16 Forecast of Global Bone & Growth Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 3.17 Forecast of Global Oncology Peptide Therapy Market Value 2022-2031 (in USD billion)
  • Exhibit 3.18 Forecast of Global Oncology Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 3.19 Forecast of Global Other Peptide Therapies Market Value 2022-2031 (in USD billion)
  • Exhibit 3.20 Forecast of Global Other Peptide Therapies Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 4.1 Segment by Application Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
  • Exhibit 4.2 Segment by Application Market Share in Global Peptide Therapy Market 2026 (in % and Billion Dosage Units)
  • Exhibit 4.3 Segment by Application Wise Value CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
  • Exhibit 4.4 Segment by Application Wise Volume CAGR Growth Rate in Global Peptide Therapy 2026-2031 (in %)
  • Exhibit 4.5 Forecast of Global Diabetes & Obesity Market Value 2022-2031 (in USD billion)
  • Exhibit 4.6 Forecast of Global Diabetes & Obesity Market Volume 2022-2031 (in Billion Dosage Units)
  • Exhibit 4.7 Forecast of Global Oncology (Cancer Treatment) Market Value 2022-2031 (in USD billion)
  • Exhibit 4.8 Forecast of Global Oncology (Cancer Treatment) Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 4.9 Forecast of Global Endocrinology Market Value 2022-2031 (in USD billion)
  • Exhibit 4.10 Forecast of Global Endocrinology Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 4.11 Forecast of Global reproductive health & urology Market Value 2022-2031 (in USD billion)
  • Exhibit 4.12 Forecast of Global Reproductive Health & Urology Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 4.13 Forecast of Global Immunology & Transplant Market Value 2022-2031 (in USD billion)
  • Exhibit 4.14 Forecast of Global Immunology & Transplant Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 4.15 Forecast of Global Bone Metabolism & Mineral Disorders Market Value 2022-2031 (in USD billion)
  • Exhibit 4.16 Forecast of Global Bone Metabolism & Mineral Disorders Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 4.17 Forecast of Global Rare Diseases & Orphan Conditions Market Value 2022-2031 (in USD billion)
  • Exhibit 4.18 Forecast of Global Rare Diseases & Orphan Conditions Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 4.19 Forecast of Global Other Applications Market Value 2022-2031 (in USD billion)
  • Exhibit 4.20 Forecast of Global Other Applications Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.1 Region-Wise Market Share in Global Peptide Therapy Market 2026 (in % and USD billion)
  • Exhibit 5.2 Region-Wise Market Share in Global Peptide Therapy 2026 (in % and Billion Dosage Units)
  • Exhibit 5.3 Region-Wise Value CAGR Growth Rate in Global Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.4 Region-Wise Volume CAGR Growth Rate in Global Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.5 Forecast of Asia-Pacific Peptide Therapy Market 2026-2031 (in USD billion)
  • Exhibit 5.6 Forecast of Asia-Pacific Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.7 Country-Wise Value Market Share in Asia-Pacific Peptide Therapy Market 2026 (in % and USD billion)
  • Exhibit 5.8 Country-Wise Value CAGR Growth Rate in Asia-Pacific Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.9 Country-Wise Volume Market Share in Asia-Pacific Peptide Therapy Market 2026 (in % and Billion Dosage Units)
  • Exhibit 5.10 Country-Wise Volume CAGR Growth Rate in Asia-Pacific Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.11 Forecast of China Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.12 Forecast of China Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.13 Forecast of Japan Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.14 Forecast of Japan Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.15 Forecast of India Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.16 Forecast of India Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.17 Forecast of South Korea Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.18 Forecast of South Korea Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.19 Forecast of Australia Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.20 Forecast of Australia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.21 Forecast of Rest of Asia Pacific Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.22 Forecast of Rest of Asia Pacific Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.23 Forecast of North America Peptide Therapy Market 2026-2031 (in USD billion)
  • Exhibit 5.24 Forecast of North America Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.25 Country-Wise Value Market Share in North America Peptide Therapy Market 2026 (in % and USD billion)
  • Exhibit 5.26 Country-Wise Value CAGR Growth Rate in North America Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.27 Country-Wise Volume Market Share in North America Peptide Therapy Market 2026 (in % and Billion Dosage Units)
  • Exhibit 5.28 Country-Wise Volume CAGR Growth Rate in North America Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.29 Forecast of USA Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.30 Forecast of USA Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.31 Forecast of Canada Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.32 Forecast of Canada Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.33 Forecast of Europe Peptide Therapy Market 2026-2031 (in USD billion)
  • Exhibit 5.34 Forecast of Europe Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.35 Country-Wise Value Market Share in Europe Peptide Therapy Market 2026 (in % and USD billion)
  • Exhibit 5.36 Country-Wise Value CAGR Growth Rate in Europe Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.37 Country-Wise Volume Market Share in Europe Peptide Therapy Market 2026 (in % and Billion Dosage Units)
  • Exhibit 5.38 Country-Wise Volume CAGR Growth Rate in Europe Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.39 Forecast of Germany Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.40 Forecast of Germany Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.41 Forecast of France Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.42 Forecast of France Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.43 Forecast of United Kingdom Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.44 Forecast of United Kingdom Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.45 Forecast of Italy Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.46 Forecast of Italy Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.47 Forecast of Spain Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.48 Forecast of Spain Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.49 Forecast of Rest of Europe Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.50 Forecast of Rest of Europe Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.51 Forecast of Middle East & Africa Peptide Therapy Market 2026-2031 (in USD billion)
  • Exhibit 5.52 Forecast of Middle East & Africa Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.53 Country-Wise Value Market Share in Middle East & Africa Peptide Therapy Market 2026 (in % and USD billion)
  • Exhibit 5.54 Country-Wise Value CAGR Growth Rate in Middle East & Africa Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.55 Country-Wise Volume Market Share in Middle East & Africa Peptide Therapy Market 2026 (in % and Billion Dosage Units)
  • Exhibit 5.56 Country-Wise Volume CAGR Growth Rate in Middle East & Africa Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.57 Forecast of Saudi Arabia Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.58 Forecast of Saudi Arabia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.59 Forecast of UAE Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.60 Forecast of UAE Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.61 Forecast of Israel Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.62 Forecast of Israel Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.63 Forecast of South Africa Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.64 Forecast of South Africa Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.65 Forecast of Turkey Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.66 Forecast of Turkey Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.67 Forecast of Rest of Middle East & Africa Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.68 Forecast of Rest of Middle East & Africa Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.69 Forecast of Latin America Peptide Therapy Market 2026-2031 (in USD billion)
  • Exhibit 5.70 Forecast of Latin America Peptide Therapy Market 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.71 Country-Wise Value Market Share in Latin America Peptide Therapy Market 2026 (in % and USD billion)
  • Exhibit 5.72 Country-Wise Value CAGR Growth Rate in Latin America Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.73 Country-Wise Volume Market Share in Latin America Peptide Therapy Market 2026 (in % and Billion Dosage Units)
  • Exhibit 5.74 Country-Wise Volume CAGR Growth Rate in Latin America Peptide Therapy Market 2026-2031 (in %)
  • Exhibit 5.75 Forecast of Brazil Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.76 Forecast of Brazil Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.77 Forecast of Mexico Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.78 Forecast of Mexico Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.79 Forecast of Argentina Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.80 Forecast of Argentina Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.81 Forecast of Colombia Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.82 Forecast of Colombia Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.83 Forecast of Rest of Latin America Peptide Therapy Market Value 2026-2031 (in USD billion)
  • Exhibit 5.84 Forecast of Rest of Latin America Peptide Therapy Market Volume 2026-2031 (in Billion Dosage Units)
  • Exhibit 5.85 Top 15 Countries in Peptide Therapy Market by 2031 Value (in USD billion)
  • Exhibit 8.1 Novo Nordisk A/S Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %) 2020-2025 (est.)
  • Exhibit 8.2 SWOT Analysis of Novo Nordisk A/S
  • Exhibit 8.3 Eli Lilly and Company Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.4 SWOT Analysis of Eli Lilly and Company
  • Exhibit 8.5 Novartis AG Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP)  and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.6 SWOT Analysis of Novartis AG
  • Exhibit 8.7 Ipsen SA Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP)  and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.8 SWOT Analysis of Ipsen SA
  • Exhibit 8.9 AbbVie Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.10 SWOT Analysis of AbbVie Inc.
  • Exhibit 8.11 Teva Pharmaceutical Industries Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.12 SWOT Analysis of Teva Pharmaceutical Industries
  • Exhibit 8.13 AstraZeneca plc Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.14 SWOT Analysis of AstraZeneca plc
  • Exhibit 8.15 Ferring Pharmaceuticals Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.16 SWOT Analysis of Ferring Pharmaceuticals
  • Exhibit 8.17 Pfizer Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.18 SWOT Analysis of Pfizer Inc.
  • Exhibit 8.19 Amgen Inc. Revenue (in USD billion), Volume (in Billion Dosage Units), Average Selling Price (ASP) and Gross Margin (in %)2020-2025 (est.)
  • Exhibit 8.20 SWOT Analysis of Amgen Inc.
  • Exhibit 9.1 Competitive Landscape of Key Players in the Global Peptide Therapy Market
  • Exhibit 12.1 SWOT Analysis of Global Peptide Therapy Market
  • Exhibit 13.1 Key Future Trends of Global Peptide Therapy Market

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
Published · instant download
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.